title: Circulating tumor cell counts/change for outcome prediction in patients with extensive-stage small-cell lung cancer.
abstract: OBJECTIVE
  As data on the use of circulating tumor cells (CTCs) to predict patient outcomes in extensive-stage small-cell lung cancer (ES-SCLC) remain inconclusive, we investigated the clinical value of CTC determination in an open-label, multicenter study of 91 patients with newly diagnosed ES-SCLC.
  
  
  METHODS
  Blood CTC counts were determined using the CellSearch® system at baseline, after the second cycle of chemotherapy, and on disease progression.
  
  
  CONCLUSIONS
  Following the second cycle of treatment, CTC numbers and the change in CTCs were strong, significant and independent indicators for both progression-free survival and overall survival in ES-SCLC. The CTC change was associated with both refractory disease (response to initial therapy ≤3 months) and sensitive disease (response to initial therapy >3 months).
authors.affiliation: Department of Medical Oncology, Jilin Provincial Cancer Hospital, Changchun, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Cheng
authors.affiliation: Department of Pulmonary Oncology, Affiliated Hospital of the Academy of Military Medical Sciences, Beijing, China.
authors.forename: Xiao-Qing
authors.initials: XQ
authors.lastname: Liu
authors.affiliation: Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Fan
authors.affiliation: Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
authors.forename: Yun-Peng
authors.initials: YP
authors.lastname: Liu
authors.affiliation: Translational Medicine Center, Laboratory of Oncology, Affiliated Hospital of the Academy of Military Medical Sciences, Beijing, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Medical Oncology, Jilin Provincial Cancer Hospital, Changchun, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Medical Oncology, Jilin Provincial Cancer Hospital, Changchun, China.
authors.forename: Li-Xia
authors.initials: LX
authors.lastname: Ma
authors.affiliation: Department of Medical Oncology, Jilin Provincial Cancer Hospital, Changchun, China.
authors.forename: Xian-Hong
authors.initials: XH
authors.lastname: Liu
authors.affiliation: Department of Medical Oncology, Jilin Provincial Cancer Hospital, Changchun, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Li
authors.affiliation: Department of Medical Oncology, Jilin Provincial Cancer Hospital, Changchun, China.
authors.forename: Hui-Zheng
authors.initials: HZ
authors.lastname: Bao
authors.affiliation: Department of Medical Oncology, Jilin Provincial Cancer Hospital, Changchun, China.
authors.forename: Jing-Jing
authors.initials: JJ
authors.lastname: Liu
authors.affiliation: Department of Medical Oncology, Jilin Provincial Cancer Hospital, Changchun, China.
authors.forename: Shuang
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology, Jilin Provincial Cancer Hospital, Changchun, China.
authors.forename: Chun-Jiao
authors.initials: CJ
authors.lastname: Wu
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002452:Cell Count; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D011379:Prognosis; D012372:ROC Curve; D012307:Risk Factors; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*
keywords: circulating tumor cells; prognosis; small-cell lung cancer